Opportunity ID: |
328354 |
Opportunity Number: |
RFA-IP-21-002 |
Opportunity Title: |
Expanded Surveillance for New Vaccine Preventable Diseases |
Opportunity Category: |
Discretionary |
Opportunity Category Explanation: |
|
Funding Instrument Type: |
Cooperative Agreement |
Category of Funding Activity: |
Health |
Category Explanation: |
|
CFDA Number(s): |
93.083 |
Eligible Applicants: |
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses |
Additional Information on Eligibility: |
|
Agency Code: |
HHS-CDC-HHSCDCERA |
Agency Name: |
Department of Health and Human Services Centers for Disease Control and Prevention – ERA |
Posted Date: |
Jul 29, 2020 |
Last Updated Date: |
Jul 29, 2020 |
Estimated Synopsis Post Date: |
Dec 01, 2020 |
Fiscal Year: |
2021 |
Award Ceiling: |
$1,000,000 |
Award Floor: |
$150,000 |
Estimated Total Program Funding: |
$35,000,000 |
Expected Number of Awards: |
7 |
Description: |
The purpose of this notice of funding opportunity is to solicit applications for a research cooperative agreement that will fund a network of pediatric medical institutions to conduct prospective, active surveillance for acute gastroenteritis (AGE) and acute respiratory illnesses (ARI) in inpatient and emergency department clinical settings, including healthy controls. The Core Component award will fund activities for a US pediatric vaccine-preventable, or possibly vaccine-preventable, disease surveillance system for a variety of AGE and ARI pathogens. The surveillance system will enable the assessment of pediatric infectious disease burden, understanding of the natural history of pediatric infectious disease, disease transmission dynamics, vaccine effectiveness evaluations and vaccine impact for vaccine-preventable pathogens or those having potential new vaccines in development. |
Version: |
1 |
|